-transparent.png){kind=logo}
At our department, the routine treatment of deep venous thrombosis is low molecular weight heparin (Fragmin) in doses of 80-120 anti-Xa Units/Kg body weight/12h subcutaneously. In an open study we found that anti-thrombotic efficacy of the treatment, and safety with regard to bleeding, was the same as found in controlled studies. The patient population was characterized by old age and high morbidity. Nevertheless, eight out of 30 patients (26%) could be transferred to ambulant care on day 2-4. We conclude that low molecular weight heparin facilitates out-patient care of uncomplicated cases of deep venous thrombosis.
Related Publications
A Nesvold, and
B Ly, and
U Abildgaard, and
M Stiris
January 1995,
Revue medicale de Bruxelles,
A Nesvold, and
B Ly, and
U Abildgaard, and
M Stiris
January 1989,
Haemostasis,
A Nesvold, and
B Ly, and
U Abildgaard, and
M Stiris
November 1988,
Lancet (London, England),
A Nesvold, and
B Ly, and
U Abildgaard, and
M Stiris
November 1988,
JAMA,
A Nesvold, and
B Ly, and
U Abildgaard, and
M Stiris
September 1999,
The Journal of family practice,
A Nesvold, and
B Ly, and
U Abildgaard, and
M Stiris
May 1988,
Therapie,
A Nesvold, and
B Ly, and
U Abildgaard, and
M Stiris
February 1996,
Thrombosis and haemostasis,
A Nesvold, and
B Ly, and
U Abildgaard, and
M Stiris
April 2002,
Thrombosis research,
A Nesvold, and
B Ly, and
U Abildgaard, and
M Stiris
October 1998,
The Western journal of medicine,
A Nesvold, and
B Ly, and
U Abildgaard, and
M Stiris
December 1999,
Managed care (Langhorne, Pa.),
